Subgroups in Fibromyalgia
Fibromyalgia: A Neurological Perspective
Roger
W. Kula, M.D.
The Chiari Institute, Great Neck, NY
Gowers, a neurologist, first described
FMS in 1904 as a possibly inflammatory condition. When no evidence of
inflammation could be found an association was noted with depression and
stress, the concept of “psychogenic rheumatism” was advanced (Boland 1947).
A number of studies have since established that FMS is neither a psychosomatic
nor somatiform disorder and that when present, anxiety and depression
are more likely to be the result than the cause of FMS (Goldenberg 1989,
Yunus 1994). Although FMS is now a better defined clinical syndrome, comprehensive
patient evaluation continues to include a wide differential diagnosis
including many diverse and sometimes obscure neurological and neuromuscular
conditions.
Pathological
findings in muscle in painful neuromuscular syndromes and neurophysiological
abnormalities of sleep in FMS will be reviewed. Although there have been
many abnormalities of laboratory and other tests reported in FMS, none
is sufficiently sensitive or specific to be useful diagnostically. Patients
with FMS should have a comprehensive medical evaluation as part of their
work-up. A preliminary lab screening should include CBC, ESR, Rheumatoid
factor, ANA, SPEP, IFE, Thyroid function testing (Tâ‚„, TSH), Hgb
A1C, and CK (x3). Both prescribed and surreptitious drug use should be
explored. Sleep and exercise behaviors should be examined. Clinical consideration
of a wide range of diagnostic possibilities may include: Acute or chronic
inflammatory demyelinating or axonal polyneuropathy, autonomic neuropathy,
secondary hyperparathyroidism, obstructive sleep apnea, periodic limb
movements, restless legs syndrome, Chiari I malformation, cervical spinal
stenosis, polymyalgia rheumatica, polymyositis, inclusion body myositis,
nodular fasciitis, steroid withdrawal syndrome, chronic antacid use (milk-alkali
syndrome), myoadenylate deaminase deficiency or other metabolic myopathies,
periodic paralysis, and myasthenia gravis.
New data including a comparative
symptom analyses of FMS and Chiari I malformation patients will be highlighted
(Milhorat, 1999). Poorly understood symptoms such as dysequilibrium, orthostatic
hypotension, tachycardia, musculoskeletal pain, impaired concentration,
and sleep disturbances common to patients with FMS, CFS and Chiari I malformation
will be approached from the standpoint of possibly disordered brainstem
function. Presented at
the National Fibromyalgia Research Association's Subgroups in Fibromyalgia
Symposium, September 26-27, 1999, in Portland, Oregon.